PE20170521A1 - Combinacion farmaceutica que comprende rilpivirina hcl, tenofovir disoproxil fumarato y emtricitabina - Google Patents

Combinacion farmaceutica que comprende rilpivirina hcl, tenofovir disoproxil fumarato y emtricitabina

Info

Publication number
PE20170521A1
PE20170521A1 PE2016002828A PE2016002828A PE20170521A1 PE 20170521 A1 PE20170521 A1 PE 20170521A1 PE 2016002828 A PE2016002828 A PE 2016002828A PE 2016002828 A PE2016002828 A PE 2016002828A PE 20170521 A1 PE20170521 A1 PE 20170521A1
Authority
PE
Peru
Prior art keywords
tenofovir disoproxil
disoproxil fumarate
emtricitabin
pharmaceutical combination
rilpivirine hcl
Prior art date
Application number
PE2016002828A
Other languages
English (en)
Inventor
Reza Oliyai
Lauren Wiser
Mark Menning
Original Assignee
Gilead Sciences Inc
Janssen Sciences Ireland Uc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45094284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20170521(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc, Janssen Sciences Ireland Uc filed Critical Gilead Sciences Inc
Publication of PE20170521A1 publication Critical patent/PE20170521A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se refiere a una combinacion en forma de comprimido que comprende una primera capa y una segunda capa en el que; a) la primera capa comprende rilpivirina HCl y esta sustancialmente libre de tenofovir disoproxil fumarato; b) la segunda capa comprende tenofovir disoproxil fumarato y esta sustancialmente libre de rilpivirina HCl; y c) el comprimido comprende ademas emtricitabina. Dicha combinacion farmaceutica es util en el tratamiento de infecciones virales tales como VIH
PE2016002828A 2010-11-19 2011-11-18 Combinacion farmaceutica que comprende rilpivirina hcl, tenofovir disoproxil fumarato y emtricitabina PE20170521A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41560010P 2010-11-19 2010-11-19

Publications (1)

Publication Number Publication Date
PE20170521A1 true PE20170521A1 (es) 2017-05-27

Family

ID=45094284

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2016002828A PE20170521A1 (es) 2010-11-19 2011-11-18 Combinacion farmaceutica que comprende rilpivirina hcl, tenofovir disoproxil fumarato y emtricitabina
PE2021000720A PE20211657A1 (es) 2010-11-19 2011-11-18 Composiciones terapeuticas que comprenden rilpivirina hcl y tenofovir disoproxil fumarato
PE2013001214A PE20140163A1 (es) 2010-11-19 2011-11-18 Composiciones terapeuticas que comprenden rilpivirina hcl y tenofovir disoproxil fumarato

Family Applications After (2)

Application Number Title Priority Date Filing Date
PE2021000720A PE20211657A1 (es) 2010-11-19 2011-11-18 Composiciones terapeuticas que comprenden rilpivirina hcl y tenofovir disoproxil fumarato
PE2013001214A PE20140163A1 (es) 2010-11-19 2011-11-18 Composiciones terapeuticas que comprenden rilpivirina hcl y tenofovir disoproxil fumarato

Country Status (35)

Country Link
US (1) US10857102B2 (es)
EP (2) EP2640362B2 (es)
JP (2) JP2014500261A (es)
KR (1) KR101923103B1 (es)
CN (2) CN103491948B (es)
AP (1) AP3816A (es)
AR (2) AR084500A1 (es)
AU (3) AU2011329642B2 (es)
BR (1) BR112013012245B1 (es)
CA (1) CA2818097C (es)
CL (1) CL2013001402A1 (es)
CO (1) CO6761300A2 (es)
CR (1) CR20130293A (es)
DK (1) DK2640362T4 (es)
EA (2) EA201691695A1 (es)
EC (2) ECSP13012700A (es)
ES (1) ES2524408T5 (es)
HK (2) HK1190064A1 (es)
HR (1) HRP20140946T1 (es)
IL (1) IL226300B (es)
MA (1) MA34735B1 (es)
ME (1) ME01980B (es)
MX (1) MX347512B (es)
MY (1) MY185604A (es)
NZ (1) NZ610729A (es)
PE (3) PE20170521A1 (es)
PL (1) PL2640362T5 (es)
PT (1) PT2640362E (es)
RS (1) RS53691B1 (es)
SG (3) SG10201509521WA (es)
SM (1) SMT201400150B (es)
TW (1) TWI556840B (es)
UA (1) UA114075C2 (es)
WO (1) WO2012068535A1 (es)
ZA (1) ZA201304481B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3025718A1 (en) 2003-01-14 2016-06-01 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
BR112013012245B1 (pt) 2010-11-19 2022-09-27 Janssen Sciences Ireland Uc Comprimido compreendendo hcl de rilpivirina e fumarato de tenofovir disoproxila seu uso no tratamento profilático ou terapêutico de uma infecção por hiv
UA115311C2 (uk) 2011-08-16 2017-10-25 Гіліад Сайєнсіз, Інк. Геміфумарат тенофовіру алафенаміду
CA2779052A1 (en) * 2012-05-31 2013-11-30 Pharmascience Inc. Pharmaceutical composition of entecavir and process of manufacturing
CA3012242C (en) 2012-12-21 2021-11-02 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
WO2015014737A1 (en) * 2013-07-29 2015-02-05 Sanovel Ilac Sanayi Ve Ticaret A.S. Multilayer tablet formulations comprising tenofovir and entecavir
CZ2013985A3 (cs) * 2013-12-09 2015-06-17 Zentiva, K.S. Stabilní farmaceutická kompozice obsahující tenofovir disoproxil fumarát
WO2015152433A1 (en) * 2014-03-31 2015-10-08 Hanmi Pharm. Co., Ltd. Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same
SG11201705069YA (en) 2014-12-26 2017-07-28 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
US9839212B2 (en) 2015-04-16 2017-12-12 Bio-Lab, Inc. Multicomponent and multilayer compacted tablets
CA2921336A1 (en) * 2015-06-30 2016-12-30 Gilead Sciences, Inc. Pharmaceutical formulations
KR20170003063A (ko) * 2015-06-30 2017-01-09 한미약품 주식회사 테노포비어 디소프록실 함유 경구용 고형제제 및 그 제조방법
EP3632415A1 (en) 2015-11-09 2020-04-08 Gilead Sciences, Inc. Therapeutic compositions for treatment of human immunodeficiency virus
WO2017175855A1 (en) * 2016-04-08 2017-10-12 Shionogi & Co., Ltd. Stabilized solid dosage form
TR201617448A2 (tr) * 2016-11-29 2018-06-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Tenofovi̇r ve emtri̇si̇tabi̇n i̇çeren kati oral farmasöti̇k bi̇leşi̇mler
US10561614B2 (en) * 2017-01-27 2020-02-18 Steerlife India Private Limited Tenofovir granules
US20200113838A1 (en) * 2017-06-30 2020-04-16 Viiv Healthcare Company Combination and uses and treatments thereof
EP3706762A4 (en) 2017-12-07 2021-09-01 Emory University N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTIVIRAL USES IN RELATION TO IT
US20210000823A1 (en) * 2019-07-03 2021-01-07 Janssen Sciences Ireland Unlimited Company Methods of treating hiv
CN112137981A (zh) * 2020-11-02 2020-12-29 成都晶富医药科技有限公司 富马酸丙酚替诺福韦片及其制备工艺

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL100965A (en) 1991-02-22 1999-12-31 Univ Emory 2 - Hydroxymethyl - 5 -) 5 - Fluorocytocin - 1 - Eyal (- 1, 3 - Oxathiolane, its resolution and pharmaceuticals containing it
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
WO2003045327A2 (en) 2001-11-27 2003-06-05 Bristol-Myers Squibb Company Efavirenz tablet formulation having unique biopharmaceutical characteristics
EP3025718A1 (en) * 2003-01-14 2016-06-01 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
AU2005279158C1 (en) 2004-09-02 2010-12-16 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
EP1632232B3 (en) 2004-09-02 2022-03-30 Janssen Pharmaceutica NV Salt of 4[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) * 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
CN101309675A (zh) 2005-10-14 2008-11-19 微量技术有限公司 口服剂量组合的药品包装
RU2008128424A (ru) 2005-12-14 2010-01-20 Сипла Лимитед (In) Фармацевтическая комбинация, включающая нуклеотидный и нуклеозидный ингибиторы обратной транскриптазы (такие как тенофовир и ламивудин) в различных частях дозы
MX2009008935A (es) * 2007-02-23 2009-11-02 Gilead Sciences Inc Moduladores de las propiedades farmacocineticas de productos terapeuticos.
US20080286344A1 (en) 2007-05-16 2008-11-20 Olivia Darmuzey Solid form
WO2008140461A1 (en) 2007-05-16 2008-11-20 Fmc Corporation Solid form
WO2008143500A1 (en) 2007-05-22 2008-11-27 Ultimorphix Technologies B.V. Tenofovir disoproxil hemi-fumaric acid co-crystal
WO2009037449A1 (en) 2007-09-18 2009-03-26 Cipla Limited Solid pharmaceutical compositions comprising one or more herpes virus inhibitors and one or more reverse transcriptase inhibitors
WO2009106960A2 (en) 2008-02-27 2009-09-03 Aurobindo Pharma Limited Stable compositions of lamivudine, tenofovir and efavirenz
EA201591353A1 (ru) 2008-05-02 2016-01-29 Джилид Сайэнс, Инк. Применение частиц твердого носителя для улучшения технологических характеристик фармацевтического агента
PE20110994A1 (es) 2009-02-06 2012-01-24 Gilead Sciences Inc Comprimidos antivirales que comprenden elvitegravir, emtricitabina, disoproxil fumarato de tenofovir y un derivado de tiazol
NZ599402A (en) 2009-09-21 2014-02-28 Gilead Sciences Inc 2’ -fluoro substituted carba-nucleoside analogs for antiviral treatment
WO2011077100A1 (en) 2009-12-24 2011-06-30 Cipla Limited Antiretroviral composition
BR112013012245B1 (pt) 2010-11-19 2022-09-27 Janssen Sciences Ireland Uc Comprimido compreendendo hcl de rilpivirina e fumarato de tenofovir disoproxila seu uso no tratamento profilático ou terapêutico de uma infecção por hiv

Also Published As

Publication number Publication date
DK2640362T3 (en) 2014-12-01
US10857102B2 (en) 2020-12-08
MA34735B1 (fr) 2013-12-03
BR112013012245B1 (pt) 2022-09-27
SG10201912527XA (en) 2020-02-27
AP3816A (en) 2016-09-30
MX347512B (es) 2017-04-28
KR101923103B1 (ko) 2018-11-28
KR20140037799A (ko) 2014-03-27
CA2818097C (en) 2019-07-30
PT2640362E (pt) 2014-11-28
CN103491948A (zh) 2014-01-01
HRP20140946T1 (hr) 2015-02-13
EP2826466A1 (en) 2015-01-21
SG190333A1 (en) 2013-06-28
IL226300B (en) 2019-05-30
UA114075C2 (xx) 2017-04-25
EP2640362B2 (en) 2021-12-01
MY185604A (en) 2021-05-25
AR084500A1 (es) 2013-05-22
DK2640362T4 (da) 2022-03-07
ECSP19078196A (es) 2019-11-30
HK1190064A1 (en) 2014-06-27
EA201691695A1 (ru) 2017-11-30
US20130243857A1 (en) 2013-09-19
SMT201400150B (it) 2015-01-15
TW201238612A (en) 2012-10-01
CN103491948B (zh) 2016-11-02
PL2640362T3 (pl) 2015-03-31
ES2524408T5 (es) 2022-04-25
AR123409A2 (es) 2022-11-30
EA201390651A1 (ru) 2013-11-29
NZ610729A (en) 2015-10-30
AP2013006931A0 (en) 2013-06-30
AU2016208417B2 (en) 2018-04-05
EP2640362A1 (en) 2013-09-25
AU2016208417A1 (en) 2016-08-18
MX2013005669A (es) 2013-11-04
CA2818097A1 (en) 2012-05-24
AU2011329642B2 (en) 2016-08-11
CN106511357A (zh) 2017-03-22
WO2012068535A1 (en) 2012-05-24
BR112013012245A2 (pt) 2016-08-09
JP6138851B2 (ja) 2017-05-31
ME01980B (me) 2015-05-20
ES2524408T3 (es) 2014-12-09
ZA201304481B (en) 2022-03-30
ECSP13012700A (es) 2013-08-30
RS53691B1 (en) 2015-04-30
JP2015131853A (ja) 2015-07-23
HK1206592A1 (en) 2016-01-15
CR20130293A (es) 2013-10-03
AU2018202635A1 (en) 2018-05-10
PL2640362T5 (pl) 2022-05-02
JP2014500261A (ja) 2014-01-09
PE20140163A1 (es) 2014-02-08
CL2013001402A1 (es) 2013-12-27
SG10201509521WA (en) 2015-12-30
EA025852B1 (ru) 2017-02-28
TWI556840B (zh) 2016-11-11
PE20211657A1 (es) 2021-08-24
CO6761300A2 (es) 2013-09-30
AU2011329642A1 (en) 2013-05-02
EP2640362B1 (en) 2014-09-10

Similar Documents

Publication Publication Date Title
PE20170521A1 (es) Combinacion farmaceutica que comprende rilpivirina hcl, tenofovir disoproxil fumarato y emtricitabina
CL2011001885A1 (es) Tableta bicapa oral en donde la primera capa comprende al compuesto de formula i (elvitegravir) y al compuesto de formula ii, y la segunda capa comprende al compuesto de formula iii (emtricitabina) y a la sal de formula iv (sal de tenofovir); metodo para la preparacion, util en el tratar infecciones por vih.
MX363389B (es) Composicion farmaceutica que comprende ivabradina amorfa.
PE20150888A1 (es) Composicion de difenidol de liberacion prolongada
MX2012014498A (es) Composicion farmaceutica de rosuvastatina.
CN302061412S (zh) 瓶(1)
CN302061411S (zh) 瓶(2)
CN302400565S (zh) 杯子
CN302008336S (zh) 吸入器
AR092570A1 (es) Composicion oral que contiene dapoxetina como base libre
CN302008949S (zh) 高分子绷带包装袋
CN302390890S (zh) 瓶子
CN301990821S (zh) 餐盘
CN302570697S (zh) 用于医用小瓶的穿刺件
CN302060489S (zh) 脚垫
CN301719879S (zh) 项坠(he0002）
CN302394800S (zh) 医用注射器
CN302394801S (zh) 医用注射器
CN302456830S (zh) 笔项（优尚a15）
CN302306228S (zh) 护肤品瓶
CN302103867S (zh) 沙发扶手(三)
CN302542199S (zh) 汽车车身
CN302219711S (zh) 收音机
CN302372086S (zh) 移动计算机电池
CN302238608S (zh) 小弧护栏